全文获取类型
收费全文 | 2059篇 |
免费 | 208篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 76篇 |
妇产科学 | 64篇 |
基础医学 | 314篇 |
口腔科学 | 10篇 |
临床医学 | 224篇 |
内科学 | 411篇 |
皮肤病学 | 21篇 |
神经病学 | 187篇 |
特种医学 | 35篇 |
外科学 | 163篇 |
综合类 | 31篇 |
一般理论 | 2篇 |
预防医学 | 355篇 |
眼科学 | 32篇 |
药学 | 139篇 |
中国医学 | 2篇 |
肿瘤学 | 195篇 |
出版年
2022年 | 20篇 |
2021年 | 42篇 |
2020年 | 25篇 |
2019年 | 41篇 |
2018年 | 44篇 |
2017年 | 48篇 |
2016年 | 52篇 |
2015年 | 50篇 |
2014年 | 61篇 |
2013年 | 84篇 |
2012年 | 139篇 |
2011年 | 149篇 |
2010年 | 76篇 |
2009年 | 60篇 |
2008年 | 131篇 |
2007年 | 117篇 |
2006年 | 116篇 |
2005年 | 120篇 |
2004年 | 117篇 |
2003年 | 95篇 |
2002年 | 98篇 |
2001年 | 38篇 |
2000年 | 18篇 |
1999年 | 31篇 |
1998年 | 25篇 |
1997年 | 26篇 |
1996年 | 18篇 |
1995年 | 26篇 |
1994年 | 13篇 |
1993年 | 11篇 |
1992年 | 25篇 |
1991年 | 18篇 |
1990年 | 23篇 |
1989年 | 19篇 |
1988年 | 12篇 |
1987年 | 15篇 |
1986年 | 19篇 |
1985年 | 22篇 |
1984年 | 14篇 |
1983年 | 24篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1979年 | 11篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 10篇 |
1974年 | 12篇 |
1973年 | 19篇 |
1972年 | 10篇 |
1969年 | 9篇 |
排序方式: 共有2269条查询结果,搜索用时 15 毫秒
1.
We have previously reported the time trends, design and interventions in randomised controlled trials (RCTs) in cystic fibrosis (CF) from 1961 through 1997 [Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D, Randomised controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000, 29:1-7.]. We maintain an ongoing register of all RCTs and controlled clinical trials (CCTs) in CF and have noted that in the five years since 1997 there has been a 48% increase in published trials. We aimed to assess whether this increase has been associated with an improvement in design quality. All RCTs and CCTs from 1961-2002 were assessed. Two epochs were then compared, 1961-1997 and 1998-2002. For each trial we recorded the design, participant numbers and the intervention studied. 261 trials in 1998-2002 were compared with 544 trials in 1961-1997. Comparing the two epochs a similar proportion of trials were parallel, double-blind and placebo controlled; also the median number of participants was similar. In the later epoch 25% of trials were multicentre, compared with 11% previously. Whilst this recent increase in clinical trials in CF is welcome, this has not been associated with improvements in quality. The trend for an increasing proportion of trials to be multicentre is encouraging. There are however, still deficiencies in the design of clinical trials in CF. 相似文献
2.
3.
The complex enterprise of modelling prenatal exposure to cigarettes: what is ‘enough’? 总被引:1,自引:0,他引:1
Kate E. Pickett Paul J. Rathouz Vanja Dukic Kristen Kasza Marina Niessner Rosalind J. Wright Lauren S. Wakschlag 《Paediatric and perinatal epidemiology》2009,23(2):160-170
While there is a burgeoning body of research linking smoking during pregnancy to problem behaviour in offspring, a major criticism of this work has been the crude measurement of exposure in these studies (e.g. retrospective, self-reported only) that could lead to biased estimates. To address this issue, we used a pregnancy cohort with repeated prospective measures of exposure as well as biological assays to generate estimates of exposure patterns using a range of modelling techniques. In this paper we report on the analytical approaches we have developed, including patterns of exposure over time and best-estimate approaches that combine self-report and cotinine measures, and compare their predictive value in relation to different dimensions of fetal growth as a first step towards examining the utility of greater precision of exposure measurement.
Surprisingly, in this sample the more complex assessments of exposure, including biological measures, generally did not perform better than simple indicators of exposure based on repeated self-report measures, with one exception: a combined self-report cotinine 'best estimate' of third trimester exposure was uniquely associated with lower brain : body ratio. Further study is needed using more sophisticated cotinine assays and testing prediction of a range of outcomes to ascertain whether these findings represent true differences or are specific to the sample, methods and outcomes used. Such research will inform the development of guidelines for adequate exposure characterisation in developmental studies. 相似文献
Surprisingly, in this sample the more complex assessments of exposure, including biological measures, generally did not perform better than simple indicators of exposure based on repeated self-report measures, with one exception: a combined self-report cotinine 'best estimate' of third trimester exposure was uniquely associated with lower brain : body ratio. Further study is needed using more sophisticated cotinine assays and testing prediction of a range of outcomes to ascertain whether these findings represent true differences or are specific to the sample, methods and outcomes used. Such research will inform the development of guidelines for adequate exposure characterisation in developmental studies. 相似文献
4.
5.
6.
Cellular localization of the inhibitory action of relaxin against uterine spasm. 总被引:1,自引:1,他引:0
下载免费PDF全文
![点击此处可从《British journal of pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
1. The aim of this study was to determine whether the site of action of relaxin as a relaxant of rat myometrium is at the cell membrane or at an intracellular-site. Therefore, the potency of relaxin was determined against spasms reliant predominantly upon either extracellular Ca2+ or intracellular Ca2+. Uterine spasms dependent upon extracellular Ca2+ were elicited by (i) oxytocin (0.2 nM) (ii) Bay K 8644 (1 microM) in 10 mM K(+)-rich PSS and (iii) KCl (80 mM). Uterine spasm dependent upon intracellular Ca2+ was elicited by oxytocin (20 nM) in the presence of nifedipine (500 nM). The effects of relaxin against these spasmogens were compared with those of levcromakalim, nifedipine and salbutamol. 2. Relaxin (0.2-6.3 nM), levcromakalim (25-800 nM), salbutamol (1-63 nM) and nifedipine (1-250 nM) caused concentration-dependent inhibition of the spasm evoked by oxytocin (0.2 nM) and relaxin was the most potent relaxant. 3. Relaxin and nifedipine were slightly less potent against the spasm induced by Bay K 8644 (1 microM) than against spasm induced by oxytocin (0.2 nM) (15 fold and 13 fold respectively). Levcromakalim and salbutamol were equipotent against the spasm evoked by Bay K 8644 (1 microM) and that evoked by oxytocin (0.2 nM). 4. Relaxin induced only 47 +/- 7% inhibition of the KCl (80 mM)-evoked spasm at a concentration of 0.8 microM. Levcromakalim was much less potent (427 fold) against the spasm evoked by KCl (80 mM) than against the spasm evoked by oxytocin (0.2 nM). The potency of salbutamol against the spasm evoked by KCl (80 mM) was modestly reduced (14 fold) compared to that against the spasm evoked by oxytocin (0.2 nM). The potency of nifedipine against the KCl (80 mM)-evoked spasm was not different from that against the oxytocin (0.2 nM)-evoked spasm. 5. The potencies of relaxin and levcromakalim against the spasm evoked by oxytocin (20 nM) + nifedipine (500 nM) were greatly reduced (74 fold and 234 fold respectively) compared to their potencies against the spasm evoked by oxytocin (0.2 nM). The potency of salbutamol against these two spasmogens was not different. 6. Relaxin was much less potent against the spasm dependent upon intracellular Ca2+ (that induced by oxytocin (20 nM) + nifedipine (500 nM)) than against the spasms dependent upon extracellular Ca2+, those induced by oxytocin (0.2 nM) and Bay K 8644 (1 microM). In this regard, relaxin resembled levcromakalim and nifedipine rather than salbutamol. Therefore, the major site of action of relaxin appears to be located at the plasma membrane rather than at an intracellular level. The observation that relaxin was less effective against the KCl (80 mM)-induced spasm than against the oxytocin (0.2 nM)-evoked spasm may indicate that relaxin has a minor action involving K(+)-channel opening. 7. High concentrations of relaxin (up to 1 microM) induced significant inhibition of the spasm dependent upon intracellular Ca2+. Thus at high concentrations relaxin also appears to have an additional intracellular action. 相似文献
7.
Clare Bradley Rosalind Plowright John Stewart John Valentine Elke Witthaus 《Health and quality of life outcomes》2007,5(1):57
Background
The results of using status measures to identify any changes in treatment satisfaction strongly suggest a need for specific change instruments designed to overcome the ceiling effects frequently observed at baseline. Status measures may leave little room to show improvement in situations where baseline ceiling effects are observed. A change version of the DTSQ (DTSQc) is compared here with the original status (now called DTSQs) version to test the instruments' comparative ability to demonstrate change. 相似文献8.
9.
10.
Richard H. Price Jr. Zane Hollingsworth Anne B. Young John B. Penney Jr. 《Brain research》1993,602(1)
The subthalamic nucleus plays a pivotal role in the regulation of basal ganglia output. Recent electrophysiologic, lesion and immunocytochemical studies suggest that the subthalamic nucleus uses an excitatory amino acid as a neurotransmitter. After complete ablation of the subthalamic nucleus, we have examined the NMDA, AMPA, kainate and metabotropic subtypes of excitatory amino acid receptors in two major subthalamic projection areas (globus pallidus and substantia nigra pars reticulata) with quantitative autoradiography. Two weeks after ablation, binding sites for [3H]AMPA and [3H]kainate increased in substantia nigra pars reticulata ipsilateral to the lesion. In globus pallidus on the lesioned side, [3H]glutamate binding to the NMDA recognition site decreased. The results suggest that glutamate receptors regulate after interruption of subthalamic nucleus output. 相似文献